Search Results - "Persaud, Yogindra"

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) by Poulikakos, Poulikos I., Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B., Tadi, Madhavi, Wargo, Jennifer A., Flaherty, Keith T., Kelley, Mark C., Misteli, Tom, Chapman, Paul B., Sosman, Jeffrey A., Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Rosen, Neal, Solit, David B.

“…Although clinical trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance…”
Get full text

RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner by Joseph, Eric W, Pratilas, Christine A, Poulikakos, Poulikos I, Tadi, Madhavi, Wang, Weiqing, Taylor, Barry S, Halilovic, Ensar, Persaud, Yogindra, Xing, Feng, Viale, Agnes, Tsai, James, Chapman, Paul B, Bollag, Gideon, Solit, David B, Rosen, Neal

“…Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK)…”
Get full text

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition by Garcia-Rendueles, Maria E R, Ricarte-Filho, Julio C, Untch, Brian R, Landa, Iňigo, Knauf, Jeffrey A, Voza, Francesca, Smith, Vicki E, Ganly, Ian, Taylor, Barry S, Persaud, Yogindra, Oler, Gisele, Fang, Yuqiang, Jhanwar, Suresh C, Viale, Agnes, Heguy, Adriana, Huberman, Kety H, Giancotti, Filippo, Ghossein, Ronald, Fagin, James A

“…Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2,…”
Get more information

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer by JANAKIRAMAN, Manickam, VAKIANI, Efsevia, PERSAUD, Yogindra, LEVINE, Douglas A, FAGIN, James A, JHANWAR, Suresh C, MARIADASON, John M, LASH, Alex, LADANYI, Marc, SALTZ, Leonard B, HEGUY, Adriana, PATY, Philip B, ZHAOSHI ZENG, SOLIT, David B, PRATILAS, Christine A, TAYLOR, Barry S, CHITALE, Dhananjay, HALILOVIC, Ensar, WILSON, Manda, HUBERMAN, Kety, RICARTE, Julio Cezar

“…Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth…”
Get full text

Genetic predictors of MEK dependence in non-small cell lung cancer by Pratilas, Christine A, Hanrahan, Aphrothiti J, Halilovic, Ensar, Persaud, Yogindra, Soh, Junichi, Chitale, Dhananjay, Shigematsu, Hisayuki, Yamamoto, Hiromasa, Sawai, Ayana, Janakiraman, Manickam, Taylor, Barry S, Pao, William, Toyooka, Shinichi, Ladanyi, Marc, Gazdar, Adi, Rosen, Neal, Solit, David B

“…Hyperactivated extracellular signal-regulated kinase (ERK) signaling is common in human cancer and is often the result of activating mutations in BRAF, RAS,…”
Get full text

A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form by Hu, Zhongbo, Persaud, Yogindra, Ahuja, Sanjay

“…Asparaginase is essential in the initial management of acute lymphoblastic leukemia (ALL) but frequently leads to venous thromboembolism (VTE). Using…”
Get full text

Pulmonary Microvascular Occlusion in Sickle Cell Disease by Abramson, Zachary, Rabe, Dawn, Persaud, Yogindra

Get full text

The Impact of Socio-Economic Determinants of Health on PedsQL and Pain Outcomes Among Individuals with Sickle Cell Disease by Persaud, Yogindra, Okhomina, Victoria, Heitzer, Andrew M, Khan, Hamda, Hodges, Jason Robert, Rai, Parul, Takemoto, Clifford M, Darbari, Deepika S., Kang, Guolian, Anghelescu, Doralina

“…Background: Pain in sickle cell disease (SCD) is the most visible symptom in patients. Many recent studies have shown that socio-economic status such as low…”
Get full text

Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim by Seddiq, Marjilla, Gadgeel, Manisha, Persaud, Yogindra, Lafferty, Jennifer, Savaşan, Süreyya

Get full text

Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis by Persaud, Yogindra, Shamoun, Mark, Chitlur, Meera, Des Rosier, Kyle J., Taub, Jeffrey W.

“…The Coronavirus Disease 2019 (COVID-19) pandemic has become the worst pandemic in modern history. The lack of prior immunity to the virus has resulted in a…”
Get full text

Attitudes Towards COVID-19 Vaccine Among Pediatric Patients with Sickle Cell Disease and their Caregivers by Persaud, Yogindra, Mandrell, Belinda N, Sharma, Akshay, Carroll, Yvonne, Irvine, Mary, Olufadi, Yunusa, Kang, Guolian, Hijano, Diego R, Rai, Parul, Hankins, Jane S., Johnson, Liza-Marie

Get full text

Bortezomib treatment of steroid‐refractory Evans syndrome in children by Beydoun, Serina B., Persaud, Yogindra, Lafferty, Jennifer, Callaghan, Michael U., Savaşan, Süreyya

“…Treatment of refractory Evans syndrome (ES) remains a challenge in hematology practice. Due to rarity of this condition, evidence‐based approaches are limited…”
Get full text

Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis by Persaud, Yogindra, Shamoun, Mark, Chitlur, Meera, Des Rosier, Kyle J., Taub, Jeffrey W.

“…The Coronavirus Disease 2019 (COVID-19) pandemic has become the worst pandemic in modern history. The lack of prior immunity to the virus has resulted in a…”
Get full text

A novel finding in pediatric leiomyosarcoma: Expanding spectrum of FGFR rearrangements in childhood cancers by Persaud, Yogindra, Bagla, Shruti, Shanti, Christina M., Shehata, Bahig M., Ravindranath, Yaddanapudi, Gorsi, Hamza S.

Get full text

Unusual Presentation of Thrombotic Thrombocytopenic Purpura in a Newly Diagnosed Pediatric Patient With Systemic Lupus Erythematosus in the Setting of MIS-C by Al-Antary, Eman T., Arar, Rewa, Persaud, Yogindra, Fathalla, Basil M., Rajpurkar, Madhvi, Bhambhani, Kanta

“…The understanding of coronavirus disease 2019 (COVID-19) immune dysregulation is evolving. Systemic lupus erythematosus (SLE) is a multisystem autoimmune…”
Get full text

Attitudes toward COVID‐19 vaccine among pediatric patients with sickle cell disease and their caregivers by Persaud, Yogindra, Mandrell, Belinda N., Sharma, Akshay, Carroll, Yvonne, Irvine, Mary, Olufadi, Yunusa, Kang, Guolian, Hijano, Diego R., Rai, Parul, Hankins, Jane S., Johnson, Liza‐Marie

“…Objective To evaluate attitudes toward vaccination and vaccine uptake regarding coronavirus disease 2019 (COVID‐19) among pediatric patients with sickle cell…”
Get full text

Unusual clinical behavior of a very late retinoblastoma relapse in a patient with a germline RB mutation by Persaud, Yogindra, Seddiq, Marjilla, Wu, Yi‐Mi, Robinson, Dan R., Poulik, Janet, Altinok, Deniz, Roarty, John D., Mody, Rajen, Taub, Jeffrey W.

Get full text

Abstract 3562: Loss of the PTEN and RB1 tumor suppressors attenuates RAF-dependence in melanomas by Xing, Feng, Persaud, Yogindra, Pratilas, Christine A., Taylor, Barry S., Janakiraman, Manickam, She, Qing-Bai, Cobrinik, David, Solit, David B.

“…Abstract Oncogenic BRAF mutations are found in ∼8% of human tumors, with the highest frequency observed in melanoma (40-70%). BRAF mutations are common in nevi…”
Get full text

Abstract LB-419: An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032 by Poulikakos, Poulikos I., Persaud, Yogindra, Gabay, May Tal, Janakiraman, Manickam, Joseph, Eric W., Pratilas, Christine A., Chapman, Paul B., Rosen, Neal, Solit, David B.

“…Abstract Drugs that compete with ATP for binding to RAF selectively inhibit ERK signaling in tumor cells with BRAF(V600E) mutation. In BRAF wild-type cells,…”
Get full text

Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors by Poulikakos, Poulikos I., Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B., Tadi, Madhavi, Wargo, Jennifer A., Flaherty, Keith T., Kelley, Mark C., Misteli, Tom, Chapman, Paul B., Sosman, Jeffrey A., Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Rosen, Neal, Solit, David B.

“…Abstract Over 50% of melanomas harbor activating mutations in BRAF, most commonly BRAF(V600E). Profound clinical activity has been observed with RAF…”
Get full text